Abstract: A system and method of providing personalized medication dosing recommendations are provided. The web-based pharmacogenomics tool includes a system and method for analyzing a patient's genomic information and producing a personalized report containing recommendations to adjust medication selection and dosing for the patient based upon known pharmacogenomic interactions. The tool is adapted to receive a whole genome screening file from a user, use Stargazer to detect diplotypes in specific pharmacogenes: assigning allele functionality, phenotype, drug names, and recommended dosage information based upon the detected diplotypes, and generating a personalized pharmacogenomics report including recommendations of medications to use or avoid and/or suggested dosing adjustments. The tool allows users to submit genomic information in either hg48 or hg19 format.

Abstract: Methods of inhibiting MMP-9 are provided. The methods of inhibiting MMP-9 include methods of inhibiting IL-6/TNF-? crosstalk mediated expression and/or secretion of MMP-9. The inhibition of the IL-6/TNF-? crosstalk pathway may be accomplished using an IL-6 signaling inhibitor, such as AG490 or SC-144. The methods may also include the treatment of dieses through the inhibition of IL-6/TNF-? crosstalk mediated production of MMP-9. In an embodiment the methods may include preventing the progression of cancer or cardiovascular disease through the inhibition of the IL-6/TNF-? crosstalk pathway.

Abstract: The microRNA ANGPTL3 inhibitor includes methods of administering a miRNA capable of inhibiting ANGTPL3 and/or dyslipidemia to a subject in need thereof. The methods of administering the miRNA ANGPTL3 inhibitor may include administration of miRNA-181d to a subject in need thereof. The administration of miRNA-181d may inhibit ANGPTL3 activity, thereby reducing ANGPTL3's inhibition of lipoprotein lipase activity and increasing triglyceride degradation. The administration of miRNA-181d may be used to treat or prevent lipid metabolism disorders including dyslipidemia and dyslipidemia associated diseases, such as hyperlipidemia, atherosclerosis, heart disease, and the like.

Abstract: The microRNA dyslipidemia inhibitor includes methods of administering a miRNA capable of inhibiting dyslipidemia to a subject in need thereof. The methods of the miRNA dyslipidemia inhibitor may include administration of miRNA-103 to a subject in need thereof. The administration of miRNA-103 may inhibit ANGPTL8 activity, thereby reducing ANGPTL8's inhibition of lipoprotein lipase activity and increasing triglyceride degradation. The administration of miRNA-103 may be used to treat or prevent lipid metabolism disorders including dyslipidemia and dyslipidemia associated diseases, such as hyperlipidemia, atherosclerosis, heart disease, and the like.

Abstract: The method for preventing progression to metabolic syndrome includes determining whether a subject possesses at least one allele of the caveolin-1 rs1997623 C to A SNP, and providing an intervention to prevent progression to metabolic syndrome, including modifications of diet and exercise, administration of one or more pharmaceutical compounds, or a combination thereof. The method may be useful to reduce the risk of developing complications associated with MetS, such as heart disease, stroke, or diabetes. The method may include monitoring additional metabolic risk factors. The pharmaceutical compound may be a pharmaceutical capable of inhibiting the expression of caveolin-1.

Abstract: The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18?-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

Abstract: The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18?-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

Abstract: The method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer (CRC) can include detecting a level of at least one indicator of metastatic potential in a biological sample from the patient, comparing the level of the indicator of metastatic potential with a control, and identifying the patient as one who is at risk of metastatic relapse and a candidate for chemotherapy if an aberrant level of the indicator of metastatic potential in the biological sample compared to the control is detected. The at least one indicator of metastatic potential can include at least one metastasis-inducing gene and/or at least one metastasis suppressor gene. An aberrant level of the at least one indicator of metastatic potential can include a copy number gain of the metastasis-inducing gene and/or a copy number loss of the metastasis-suppressor gene.

Abstract: The method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of estrogen replacement therapy to a patient in need thereof to promote wound healing. Alternatively, the method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of a TNF-? inhibitor to a patient in need thereof to promote wound healing. The method of treating diabetes-related impaired wound healing may also include both the step of administering an effective amount of estrogen replacement therapy and administering an effective amount of a TNF-? inhibitor to a patient in need thereof to promote wound healing.

Abstract: The method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer (CRC) can include detecting a level of at least one indicator of metastatic potential in a biological sample from the patient, comparing the level of the indicator of metastatic potential with a control, and identifying the patient as one who is at risk of metastatic relapse and a candidate for chemotherapy if an aberrant level of the indicator of metastatic potential in the biological sample compared to the control is detected. The at least one indicator of metastatic potential can include at least one metastasis-inducing gene and/or at least one metastasis suppressor gene. An aberrant level of the at least one indicator of metastatic potential can include a copy number gain of the metastasis-inducing gene and/or a copy number loss of the metastasis-suppressor gene.

Abstract: The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18?-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

Abstract: The method of sub-classifying breast cancer tumors profiles the expression of the Raf kinase inhibitor protein (RKIP) from a tissue sample from a cancerous primary breast tumor. The RKIP expression is profiled using its mRNA or by immunohistochemical protein quantifying methods in order to detect the level of RKIP in the breast cancer tissue sample. Based upon the RKIP expression profile, a sub-classification of cancer type may then be assigned. An RKIP expression of approximately 10.31 indicates basal carcinoma, an RKIP expression of approximately 10.04 indicates Claudin-low carcinoma, an RKIP expression of approximately 10.47 indicates Luminal-A carcinoma, an RKIP expression of approximately 10.44 indicates Luminal-B carcinoma, an RKIP expression of approximately 10.25 indicates HER2+ carcinoma, an RKIP expression of approximately 10.43 indicates ER+ carcinoma, and an RKIP expression of approximately 10.30 indicates ER? carcinoma.

Abstract: The method of treating diabetes-related vascular complications includes the treatment of diabetic patients with ?-lipoic acid (LA) in order to mitigate the negative impact of diabetes-related vascular dysfunctions upon vascular homeostasis. The treatment method includes the step of administering to the patient an initial dosage of ?-lipoic acid believed to be therapeutically effective. The patient's response is then monitored by measuring ?-lipoic acid-responsive biomarkers and by performing assays from blood and tissue taken from the patient.

Abstract: The method of diagnosing and treating oxidative stress-impaired wound healing allows a practitioner to identify a subject at risk of having impaired wound healing by identifying the sensitivity of that patient to IGF-1. A finding of IGF-1 resistance, either systemically or at the site of an already existing wound, indicates an increased likelihood that the wound will have difficulty healing. In addition, identifying IGF-1 resistance by this method indicates that treatment of a wound with a combination of an antioxidant, IGF-1 and IGFBP-1 will provide optimal healing.

Abstract: The method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of estrogen replacement therapy to a patient in need thereof to promote wound healing. Alternatively, the method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of a TNF-? inhibitor to a patient in need thereof to promote wound healing. The method of treating diabetes-related impaired wound healing may also include both the step of administering an effective amount of estrogen replacement therapy and administering an effective amount of a TNF-? inhibitor to a patient in need thereof to promote wound healing.

Abstract: The method of treating impaired wound healing in diabetics comprises the step of administering an effective amount of a glycogen synthase kinase 3-? (GSK-3?) inhibitor to a diabetic patient in need thereof to activate the NF-E2-related factor 2 (Nrf2) and genes downstream of Nrf2 that normally regulate the expression and coordination of antioxidant responses during wound healing, but are suppressed in the diabetic patient undergoing the oxidative stress that can occur during wound healing. The GSK-3? inhibitor may be lithium or a pharmaceutically acceptable salt thereof, or TDZD-8 (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione). The method may further comprise the step of testing the diabetic patient for the presence of oxidative stress and decreased Nrf2, which enables the early or prophylactic treatment of the patient with a GSK-3? inhibitor when the patient first presents with a wound, rather than waiting for other symptoms of impaired wound healing to occur.

Abstract: The method of diagnosing and treating oxidative stress-impaired wound healing allows a practitioner to identify a subject at risk of having impaired wound healing by identifying the sensitivity of that patient to IGF-1. A finding of IGF-1 resistance, either systemically or at the site of an already existing wound, indicates an increased likelihood that the wound will have difficulty healing. In addition, identifying IGF-1 resistance by this method indicates that treatment of a wound with a combination of an antioxidant, IGF-1 and IGFBP-1 will provide optimal healing.

Abstract: The method of treating diabetes-related vascular complications includes the treatment of diabetic patients with ?-lipoic acid (LA) in order to mitigate the negative impact of diabetes-related vascular dysfunctions upon vascular homeostasis. The treatment method includes the step of administering to the patient an initial dosage of ?-lipoic acid believed to be therapeutically effective. The patient's response is then monitored by measuring ?-lipoic acid-responsive biomarkers and by performing assays from blood and tissue taken from the patient.

Abstract: The present invention relates to the prediction of metastasis by determining RKIP expression levels, and to products and kits adapted for such methods. In some embodiments, the present invention relates to methods of assigning a treatment or monitoring regime to a cancer patient according to the level of RKIP expression.